• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evolus, Inc. - Common Stock (NQ:EOLS)

9.080 -0.010 (-0.11%)
Streaming Delayed Price Updated: 2:57 PM EDT, Sep 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 321,933
Open 9.040
Bid (Size) 9.080 (300)
Ask (Size) 9.090 (400)
Prev. Close 9.090
Today's Range 8.930 - 9.124
52wk Range 3.860 - 9.150
Shares Outstanding 54,576,156
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Telix Appoints David Gill as Chair
August 31, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Evolus Q2 Earnings Call Highlights ↗
August 05, 2026
Evolus (NASDAQ:EOLS) reported second-quarter revenue growth of 21% and raised the lower end of its full-year 2026 revenue outlook, citing market-share gains in neurotoxins and hyaluronic acid... 
Via MarketBeat
Topics Earnings

Performance

YTD
+35.1%
+35.1%
1 Month
+50.1%
+50.1%
3 Month
+39.3%
+39.3%
6 Month
+111.7%
+111.7%
1 Year
+21.1%
+21.1%

More News

Read More
Evolus (NASDAQ:EOLS) Tops Q2 EPS Estimates and Raises Revenue Guidance, Shares Gain 5.7% ↗
August 05, 2026
Via Chartmill
News headline image
Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
August 05, 2026
From Evolus
Via Business Wire
News headline image
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
August 04, 2026
From Evolus
Via Business Wire
Evolus Inc (NASDAQ:EOLS) Q1 2026 Earnings: Narrowed Loss and Positive EBITDA Drive After-Hours Rally ↗
May 04, 2026
Via Chartmill
Evolus Inc (NASDAQ:EOLS) Reports Q4 2025 Earnings Beat and Path to 2026 Profitability ↗
March 03, 2026
Via Chartmill
Topics Earnings
News headline image
Evolus to Report Second Quarter Financial Results on August 5, 2026
July 22, 2026
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026
From Evolus
Via Business Wire
News headline image
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
July 08, 2026
From Evolus
Via Business Wire
News headline image
Evolus to Participate in The Jefferies Global Healthcare Conference
May 19, 2026
From Evolus
Via Business Wire
News headline image
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
May 11, 2026
From Evolus
Via Business Wire
News headline image
Evolus (EOLS) Q1 2026 Earnings Transcript ↗
May 04, 2026
Via The Motley Fool
Topics World Trade
News headline image
Evolus (EOLS) Q2 2025 Earnings Call Transcript ↗
May 04, 2026
Via The Motley Fool
Topics Earnings World Trade
News headline image
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
May 04, 2026
From Evolus
Via Business Wire
News headline image
Evolus to Report First Quarter Financial Results on May 4, 2026
April 14, 2026
From Evolus
Via Business Wire
News headline image
Telix Appoints David Gill as Non-Executive Director
April 01, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
March 31, 2026
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 20, 2026
From Evolus
Via Business Wire
News headline image
Why Evolus Stock Soared Today ↗
March 04, 2026
Via The Motley Fool
What's going on in today's session ↗
March 04, 2026
Via Chartmill
Gapping stocks in Wednesday's session ↗
March 04, 2026
Via Chartmill
News headline image
Evolus (EOLS) Q4 2025 Earnings Call Transcript ↗
March 03, 2026
Via The Motley Fool
Topics Earnings World Trade
These stocks are moving in today's after hours session ↗
March 03, 2026
Via Chartmill
News headline image
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026
March 03, 2026
From Evolus
Via Business Wire

Frequently Asked Questions

Is Evolus, Inc. - Common Stock publicly traded?
Yes, Evolus, Inc. - Common Stock is publicly traded.
What exchange does Evolus, Inc. - Common Stock trade on?
Evolus, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Evolus, Inc. - Common Stock?
The ticker symbol for Evolus, Inc. - Common Stock is EOLS on the Nasdaq Stock Market
What is the current price of Evolus, Inc. - Common Stock?
The current price of Evolus, Inc. - Common Stock is 9.080
When was Evolus, Inc. - Common Stock last traded?
The last trade of Evolus, Inc. - Common Stock was at 09/01/26 02:57 PM ET
What is the market capitalization of Evolus, Inc. - Common Stock?
The market capitalization of Evolus, Inc. - Common Stock is 495.55M
How many shares of Evolus, Inc. - Common Stock are outstanding?
Evolus, Inc. - Common Stock has 496M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap